echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The original research has wiped out the entire army of Guangdong's chronic disease drugs. The results are here!

    The original research has wiped out the entire army of Guangdong's chronic disease drugs. The results are here!

    • Last Update: 2022-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Five varieties including clindamycin, memantine, cefixime, cefoxitin, and Bao'eran granules were sold out, and 8 original research companies were wiped out
    .
    Next, the hospital began to report the quantity.
    Is this really purchasing with quantity?
     
    Just yesterday, the results of the 276 western medicines (the first batch) were announced.
    Then, the results of the 87 common and chronic diseases in the 7-province alliance of Guangdong were also announced! The announcement time is from March 11 to 15 at 17:00
    .
     
    The seven provinces include: Guangdong, Shanxi, Henan, Jiangxi, Inner Mongolia, Xinjiang and the Corps
     
    Only 8 original research companies signed up, but the whole army was wiped out
     
    From the perspective of procurement rules, there is no distinction between the original research and reference preparations in terms of grouping.
    If the original research and reference preparations have been evaluated in the same group, they are considered to be over-evaluated; if the same group has no over-evaluation, they will be merged.
    For the non-overrated category
    .
     
    Judging from the registration situation of qualified original research manufacturers, only 8 enterprises signed up, but unfortunately, all these original research enterprises were not selected!
     
     
      In addition, 5 varieties of clindamycin, memantine, cefixime, cefoxitin, and Bao'eran granules were out of standard
    .
     
      Guangdong took the lead in the centralized procurement of 87 common and chronic diseases in 7 provinces.
    It can be said that it has collected general medicines that meet the requirements for centralized procurement in all provinces, including 24 antibiotics and 3 proprietary Chinese medicines
    .
     
      Because it is an old variety and there are many manufacturers, a total of 290 companies and 1,198 product specifications meet the application requirements
    .
    Among them, Baiyunshan Tianxin and other 12 manufacturers involved more than 10 varieties, 19 groups involved more than 10 enterprises, 50% reduction requirement, non-exclusive elimination rate of more than 70%, the intensity of competition in this centralized procurement can be imagined know
    .
     
      As a result, 16 candidates from Baiyunshan Tianxin Pharmaceutical were selected, 12 candidates from Ruiyang Pharmaceutical, and 11 candidates from Sinopharm Rongsheng, Xinxiang Changle Pharmaceutical, and Huazhong Pharmaceutical
    .
     
      As shown in the table below:
     
     
      The number of antibiotics in this alliance's centralized procurement is as high as 24, and the number of companies to be selected is also shocking
    .
    Among them, 28 companies of gentamicin are to be selected, 20 companies of akamicin and 19 companies of lincomycin
    .
     
      According to the rules, after the results of the selection are made, medical institutions will select specific procurement varieties according to the results.
    It is conceivable that the prices of these varieties have generally dropped by more than 50%, but how much hospital procurement share can be allocated? More monks and less porridge is certain
    .
     
      However, there are relatively lucky ones
    .
    Amoxicillin, clavulanic acid, and cefpiramide are all 3 to be selected; erythromycin ethylsuccinate, cefoperazone, cefpiramide, cefprozil, tobramycin, erythromycin ethylsuccinate, and cefmenoxime are 2 The family intends to be selected; while spectinomycin, cefnicil, and roxithromycin are the exclusive candidates to be selected
    .
     
     
      Three Chinese patent medicines, one of Liubiao (Baoeran Granules), and the other selected Huazhi Suppository and Qingre Xiaoyanning Capsules are planned to be selected by Guangdong enterprises, as shown in the following table:
     
     
      summary:
     
      1.
    The centralized procurement of 87 medicines for common diseases and chronic diseases in 7 provinces of Guangdong.
    The biggest feature is that medical institutions do not start to report the demand until after the selection.
    Therefore, it is difficult to say that this is a real volume procurement
    .
    Affected by this, some companies lack motivation to participate, the original research was wiped out and the failure of some varieties may have something to do with it;
     
      2.
    Since the registration conditions are relatively loose, almost all companies with approval documents can participate, so there are many manufacturers and the competition is fierce
    .
    Therefore, once it is decided to seize the access opportunity of the seven provinces, some companies will not hesitate to reduce the price, but in fact they only get one access quota by reducing the price;
     
      3.
    The centralized procurement of drugs for common diseases and chronic diseases is the premise for the development of long-term prescriptions for chronic diseases, dual-channel, and Internet hospital follow-up visits.
    Only by fully reducing prices and having sufficient drug suppliers can the circulation of prescriptions and medical insurance payment be ensured.
    sustainable;
     
      4.
    So far, Guangdong has carried out two batches of 233 varieties (146+87) in just one week.
    The speed is fast to show the potential of accumulation.
    However, the number of standard varieties is also more than 10.
    Worth watching
    .
      Five varieties including clindamycin, memantine, cefixime, cefoxitin, and Bao'eran granules were sold out, and 8 original research companies were wiped out
    .
    Next, the hospital began to report the quantity.
    Is this really purchasing with quantity?
     
      Just yesterday, the results of the 276 western medicines (the first batch) were announced.
    Then, the results of the 87 common and chronic diseases in the 7-province alliance of Guangdong were also announced! The announcement time is from March 11 to 15 at 17:00
    .
     
      The seven provinces include: Guangdong, Shanxi, Henan, Jiangxi, Inner Mongolia, Xinjiang and the Corps
     
      Only 8 original research companies signed up, but the whole army was wiped out
     
      From the perspective of procurement rules, there is no distinction between the original research and reference preparations in terms of grouping.
    If the original research and reference preparations have been evaluated in the same group, they are considered to be over-evaluated; if the same group has no over-evaluation, they will be merged.
    For the non-overrated category
    .
     
      Judging from the registration situation of qualified original research manufacturers, only 8 enterprises signed up, but unfortunately, all these original research enterprises were not selected!
     
     
      In addition, 5 varieties of clindamycin, memantine, cefixime, cefoxitin, and Bao'eran granules were out of standard
    .
     
      Guangdong took the lead in the centralized procurement of 87 common and chronic diseases in 7 provinces.
    It can be said that it has collected general medicines that meet the requirements for centralized procurement in all provinces, including 24 antibiotics and 3 proprietary Chinese medicines
    .
     
      Because it is an old variety and there are many manufacturers, a total of 290 companies and 1,198 product specifications meet the application requirements
    .
    Among them, Baiyunshan Tianxin and other 12 manufacturers involved more than 10 varieties, 19 groups involved more than 10 enterprises, 50% reduction requirement, non-exclusive elimination rate of more than 70%, the intensity of competition in this centralized procurement can be imagined know
    .
     
      As a result, 16 candidates from Baiyunshan Tianxin Pharmaceutical were selected, 12 candidates from Ruiyang Pharmaceutical, and 11 candidates from Sinopharm Rongsheng, Xinxiang Changle Pharmaceutical, and Huazhong Pharmaceutical
    .
     
      As shown in the table below:
     
     
      The number of antibiotics in this alliance's centralized procurement is as high as 24, and the number of companies to be selected is also shocking
    .
    Among them, 28 companies of gentamicin are to be selected, 20 companies of akamicin and 19 companies of lincomycin
    .
     
      According to the rules, after the results of the selection are made, medical institutions will select specific procurement varieties according to the results.
    It is conceivable that the prices of these varieties have generally dropped by more than 50%, but how much hospital procurement share can be allocated? More monks and less porridge is certain
    .
     
      However, there are relatively lucky ones
    .
    Amoxicillin, clavulanic acid, and cefpiramide are all 3 to be selected; erythromycin ethylsuccinate, cefoperazone, cefpiramide, cefprozil, tobramycin, erythromycin ethylsuccinate, and cefmenoxime are 2 The family intends to be selected; while spectinomycin, cefnicil, and roxithromycin are the exclusive candidates to be selected
    .
     
     
      Three Chinese patent medicines, one of Liubiao (Baoeran Granules), and the other selected Huazhi Suppository and Qingre Xiaoyanning Capsules are planned to be selected by Guangdong enterprises, as shown in the following table:
     
     
      summary:
     
      1.
    The centralized procurement of 87 medicines for common diseases and chronic diseases in 7 provinces of Guangdong.
    The biggest feature is that medical institutions do not start to report the demand until after the selection.
    Therefore, it is difficult to say that this is a real volume procurement
    .
    Affected by this, some companies lack motivation to participate, the original research was wiped out and the failure of some varieties may have something to do with it;
     
      2.
    Since the registration conditions are relatively loose, almost all companies with approval documents can participate, so there are many manufacturers and the competition is fierce
    .
    Therefore, once it is decided to seize the access opportunity of the seven provinces, some companies will not hesitate to reduce the price, but in fact they only get one access quota by reducing the price;
     
      3.
    The centralized procurement of drugs for common diseases and chronic diseases is the premise for the development of long-term prescriptions for chronic diseases, dual-channel, and Internet hospital follow-up visits.
    Only by fully reducing prices and having sufficient drug suppliers can the circulation of prescriptions and medical insurance payment be ensured.
    sustainable;
     
      4.
    So far, Guangdong has carried out two batches of 233 varieties (146+87) in just one week.
    The speed is fast to show the potential of accumulation.
    However, the number of standard varieties is also more than 10.
    Worth watching
    .
      Five varieties including clindamycin, memantine, cefixime, cefoxitin, and Bao'eran granules were sold out, and 8 original research companies were wiped out
    .
    Next, the hospital began to report the quantity.
    Is this really purchasing with quantity?
     
      Just yesterday, the results of the 276 western medicines (the first batch) were announced.
    Then, the results of the 87 common and chronic diseases in the 7-province alliance of Guangdong were also announced! The announcement time is from March 11 to 15 at 17:00
    .
    medicines medicines medicines
     
      The seven provinces include: Guangdong, Shanxi, Henan, Jiangxi, Inner Mongolia, Xinjiang and the Corps
      The seven provinces include: Guangdong, Shanxi, Henan, Jiangxi, Inner Mongolia, Xinjiang and the Corps
     
      Only 8 original research companies signed up, but the whole army was wiped out
      Only 8 original research companies signed up , but the whole army was wiped out
     
      From the perspective of procurement rules, there is no distinction between the original research and reference preparations in terms of grouping.
    If the original research and reference preparations have been evaluated in the same group, they are considered to be over-evaluated; if the same group has no over-evaluation, they will be merged.
    For the non-overrated category
    .
     
      Judging from the registration situation of qualified original research manufacturers, only 8 enterprises signed up, but unfortunately, all these original research enterprises were not selected!
     
     
      In addition, 5 varieties of clindamycin, memantine, cefixime, cefoxitin, and Bao'eran granules were out of standard
    .
     
      Guangdong took the lead in the centralized procurement of 87 common and chronic diseases in 7 provinces.
    It can be said that it has collected general medicines that meet the requirements for centralized procurement in all provinces, including 24 antibiotics and 3 proprietary Chinese medicines
    .
     
      Because it is an old variety and there are many manufacturers, a total of 290 companies and 1,198 product specifications meet the application requirements
    .
    Among them, Baiyunshan Tianxin and other 12 manufacturers involved more than 10 varieties, 19 groups involved more than 10 enterprises, 50% reduction requirement, non-exclusive elimination rate of more than 70%, the intensity of competition in this centralized procurement can be imagined know
    .
     
      As a result, 16 candidates from Baiyunshan Tianxin Pharmaceutical were selected, 12 candidates from Ruiyang Pharmaceutical, and 11 candidates from Sinopharm Rongsheng, Xinxiang Changle Pharmaceutical, and Huazhong Pharmaceutical
    .
     
      As shown in the table below:
     
     
     
      The number of antibiotics in this alliance's centralized procurement is as high as 24, and the number of companies to be selected is also shocking
    .
    Among them, 28 companies of gentamicin are to be selected, 20 companies of akamicin and 19 companies of lincomycin
    .
     
      According to the rules, after the results of the selection are made, medical institutions will select specific procurement varieties according to the results.
    It is conceivable that the prices of these varieties have generally dropped by more than 50%, but how much hospital procurement share can be allocated? More monks and less porridge is certain
    .
    Hospital Procurement Hospital Hospital Procurement _
     
      However, there are relatively lucky ones
    .
    Amoxicillin, clavulanic acid, and cefpiramide are all 3 to be selected; erythromycin ethylsuccinate, cefoperazone, cefpiramide, cefprozil, tobramycin, erythromycin ethylsuccinate, and cefmenoxime are 2 The family intends to be selected; while spectinomycin, cefnicil, and roxithromycin are the exclusive candidates to be selected
    .
     
     
      Three Chinese patent medicines, one of Liubiao (Baoeran Granules), and the other selected Huazhi Suppository and Qingre Xiaoyanning Capsules are planned to be selected by Guangdong enterprises, as shown in the following table:
     
     
      summary:
      summary:
     
      1.
    The centralized procurement of 87 medicines for common diseases and chronic diseases in 7 provinces of Guangdong.
    The biggest feature is that medical institutions do not start to report the demand until after the selection.
    Therefore, it is difficult to say that this is a real volume procurement
    .
    Affected by this, some companies lack motivation to participate, the original research was wiped out and the failure of some varieties may have something to do with it;
     
      2.
    Since the registration conditions are relatively loose, almost all companies with approval documents can participate, so there are many manufacturers and the competition is fierce
    .
    Therefore, once it is decided to seize the access opportunity of the seven provinces, some companies will not hesitate to reduce the price, but in fact they only get one access quota by reducing the price;
     
      3.
    The centralized procurement of drugs for common diseases and chronic diseases is the premise for the development of long-term prescriptions for chronic diseases, dual-channel, and Internet hospital follow-up visits.
    Only by fully reducing prices and having sufficient drug suppliers can the circulation of prescriptions and medical insurance payment be ensured.
    sustainable;
     
      4.
    So far, Guangdong has carried out two batches of 233 varieties (146+87) in just one week.
    The speed is fast to show the potential of accumulation.
    However, the number of standard varieties is also more than 10.
    Worth watching
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.